저용량의 corticosteroid 복용이 B형 간염 바이러스재활성화에 미치는 영향
The effect of low dose corticosteroid therapy on viral reactivation in patients with chronic hepatitis B virus infection
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims : We investigated the effect of low dose corticosteroid therapy on HBV reactivation in patients with chronic HBV infection. Methods : From August 1998 to March 2007, the HBsAg-positive patients who received oral or intravenous corticosteroid therapy for more than 1 week at Samsung Medical Center were included in this retrospective study. We included those patients who received anticancer chemotherapy or organ transplantation, or concurrent antiviral therapy or other immunosuppressive agents. HBV reactivation was defined as a 10-fold increase in the HBV DNA levels compared with baseline. Results : A total of 16 patients were included. They were 45.4±16.7 years of age, and the male:female ratio was 14:2. Their combined diseases included bronchial asthma, allergic urticaria, allergic rhinitis, etc. The corticosteroid doses were converted to prednisolone equivalent doses and these varied from 2.5 mg to 50 mg per day. Eleven patients used less than 20 mg of prednisolone per day. The mean medication duration was 60.1 days (range: 7-364 days). Among the patients, only one patient showed HBV reactivation. This ankylosing spondylitis patient was a 31-year old man who took prednisolone 5 mg/day for 364 days. He displayed HBeAg-positivity before corticosteroid treatment. There was no aggravation of the levels of ALT, albumin, bilirubin, and PT between the pre-and post-medication in this patient. Conclusions : The short term use of low dose corticosteroid is not likely to be related with HBV reactivation in those patients with chronic HBV infection, yet long term use may lead to viral reactivation. Further large scaled, prospective studies on this subject are needed. (Korean J Med 74:619-623, 2008)
Abstract
Background/Aims : We investigated the effect of low dose corticosteroid therapy on HBV reactivation in patients with chronic HBV infection. Methods : From August 1998 to March 2007, the HBsAg-positive patients who received oral or intravenous corticosteroid therapy for more than 1 week at Samsung Medical Center were included in this retrospective study. We included those patients who received anticancer chemotherapy or organ transplantation, or concurrent antiviral therapy or other immunosuppressive agents. HBV reactivation was defined as a 10-fold increase in the HBV DNA levels compared with baseline. Results : A total of 16 patients were included. They were 45.4±16.7 years of age, and the male:female ratio was 14:2. Their combined diseases included bronchial asthma, allergic urticaria, allergic rhinitis, etc. The corticosteroid doses were converted to prednisolone equivalent doses and these varied from 2.5 mg to 50 mg per day. Eleven patients used less than 20 mg of prednisolone per day. The mean medication duration was 60.1 days (range: 7-364 days). Among the patients, only one patient showed HBV reactivation. This ankylosing spondylitis patient was a 31-year old man who took prednisolone 5 mg/day for 364 days. He displayed HBeAg-positivity before corticosteroid treatment. There was no aggravation of the levels of ALT, albumin, bilirubin, and PT between the pre-and post-medication in this patient. Conclusions : The short term use of low dose corticosteroid is not likely to be related with HBV reactivation in those patients with chronic HBV infection, yet long term use may lead to viral reactivation. Further large scaled, prospective studies on this subject are needed. (Korean J Med 74:619-623, 2008)
참고문헌 (22)
- Hoofnagle JH, "Reactivation of chronic hepatitis B virus infection by cancer chemotherapy", Ann Intern Med, 96, pp.447~449 (1982)
- Vento S, "Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue", Lancet Oncol, 3, pp.333~340 (2002)
- Yeo W, "Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy", Ann Oncol, 15, pp.1661~1666 (2004)
- Lok AS, "Chronic hepatitis B", Hepatology, 45, pp.507~539 (2007)
- Yeo W, "Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy", Hepatology, 43, pp.209~220 (2006)
- Lau GK, "Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation", Hepatology, 36, pp.702~709 (2002)
- Lau GK, "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy", Gastroenterology, 125, pp.1742~1749 (2003)
- Rossi G, "Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy", Br J Haematol, 115, pp.58~62 (2001)
- Chan TM, "Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients", Hepatology, 36, pp.1243~1252 (2002)
- Cheng AL, "Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma", Hepatology, 37, pp.1320~1328 (2003)
- Lok AS, "Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study", Gastroenterology, 100, pp.182~188 (1991)
- Fornairon S, "The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection", Transplantation, 62, pp.297~299 (1996)
- Perrillo RP, "Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease", Gastroenterology, 120, pp.1009~1022 (2001)
- Tur-Kaspa R, "Hepatitis B virus DNA contains a glucocorticoid-responsive element", Proc Natl Acad Sci U S A, 83, pp.1627~1631 (1986)
- Tur-Kaspa R, "The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer", Virology, 167, pp.630~633 (1988)
- Chou CK, "Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells", Hepatology, 16, pp.13~18 (1992)
- Rossi G, "Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato- oncological neoplasias treated with chemotherapy", Leuk Lymphoma, 44, pp.759~766 (2003)
- Lau GK, "High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation", Blood, 99, pp.2324~2330 (2002)
- Jang JW, "Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma", J Hepatol, 41, pp.427~435 (2004)
- Esteve M, "Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis", Gut, 53, pp.1363~1365 (2004)
- Ostuni P, "Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate", Ann Rheum Dis, 62, pp.686~687 (2003)
- Yeo W, "Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors", J Med Virol, 62, pp.299~307 (2000)